Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Fri May 2, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nutriband (NTRB – Research Report) and Opko Health (OPK – Research Report) with bullish sentiments.

Protect Your Portfolio Against Market Uncertainty

Nutriband (NTRB)

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Nutriband today and set a price target of $13.00. The company’s shares closed last Thursday at $6.94.

According to TipRanks.com, LeBoyer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.5% and a 25.8% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Cadrenal Therapeutics, Inc., MAIA Biotechnology, Inc., and Eledon Pharmaceuticals. ;'>

Nutriband has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.

See Insiders’ Hot Stocks on TipRanks >>

Opko Health (OPK)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health, with a price target of $2.25. The company’s shares closed last Thursday at $1.31.

According to TipRanks.com, Petusky is a 3-star analyst with an average return of 1.4% and a 44.3% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, US Physical Therapy, and Lifecore Biomedical. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Opko Health with a $2.56 average price target, representing an 85.5% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.

Read More on NTRB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).